These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23682235)

  • 1. The renoprotective effects of pentoxifylline: beyond its role in diabetic nephropathy.
    Kapoor S
    Korean J Intern Med; 2013 May; 28(3):374-5. PubMed ID: 23682235
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of phosphodiesterase inhibitor on diabetic nephropathy.
    Kang SW
    Korean J Intern Med; 2012 Jun; 27(2):151-3. PubMed ID: 22707885
    [No Abstract]   [Full Text] [Related]  

  • 3. In reply.
    Sun HK; Han SY
    Korean J Intern Med; 2013 May; 28(3):375-6. PubMed ID: 23819195
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.
    Sun HK; Lee YM; Han KH; Kim HS; Ahn SH; Han SY
    Korean J Intern Med; 2012 Jun; 27(2):163-70. PubMed ID: 22707888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effect of pentoxifylline in advanced chronic kidney disease.
    Kao CC; Wu MS
    J Formos Med Assoc; 2015 Jan; 114(1):94. PubMed ID: 24974130
    [No Abstract]   [Full Text] [Related]  

  • 6. Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren-2 rats.
    Wiggins KJ; Tiauw V; Zhang Y; Gilbert RE; Langham RG; Kelly DJ
    Nephrology (Carlton); 2008 Dec; 13(8):721-9. PubMed ID: 18826488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.
    Navarro-González JF; Sánchez-Niño MD; Donate-Correa J; Martín-Núñez E; Ferri C; Pérez-Delgado N; Górriz JL; Martínez-Castelao A; Ortiz A; Mora-Fernández C
    Diabetes Care; 2018 Aug; 41(8):1817-1820. PubMed ID: 29866645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.
    Han KH; Han SY; Kim HS; Kang YS; Cha DR
    Inflammation; 2010 Jun; 33(3):137-43. PubMed ID: 19921414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorative effects of pentoxifylline on NOS induced by diabetes in rat kidney.
    Sönmez MF; Dündar M
    Ren Fail; 2016; 38(4):605-13. PubMed ID: 26905686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of phosphodiesterase inhibitors on renal functions and oxidant/antioxidant parameters in streptozocin-induced diabetic rats.
    Mehanna OM; El Askary A; Al-Shehri S; El-Esawy B
    Arch Physiol Biochem; 2018 Dec; 124(5):424-429. PubMed ID: 29271249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats.
    DiPetrillo K; Gesek FA
    Am J Nephrol; 2004; 24(3):352-9. PubMed ID: 15205554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
    He T; Cooper ME
    Nat Rev Nephrol; 2014 Oct; 10(10):547-8. PubMed ID: 25201141
    [No Abstract]   [Full Text] [Related]  

  • 13. The renoprotective potential of pentoxifylline in chronic kidney disease.
    Lin SL; Chiang WC; Chen YM; Lai CF; Tsai TJ; Hsieh BS
    J Chin Med Assoc; 2005 Mar; 68(3):99-105. PubMed ID: 15813241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the renoprotective effects of pentoxifylline and vitamin E on streptozotocin-induced diabetes mellitus.
    Dávila-Esqueda ME; Vertiz-Hernández AA; Martínez-Morales F
    Ren Fail; 2005; 27(1):115-22. PubMed ID: 15717644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus.
    Gunduz Z; Canoz O; Per H; Dusunsel R; Poyrazoglu MH; Tez C; Saraymen R
    Ren Fail; 2004 Nov; 26(6):597-605. PubMed ID: 15600249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
    Badri S; Dashti-Khavidaki S; Lessan-Pezeshki M; Abdollahi M
    J Pharm Pharm Sci; 2011; 14(1):128-37. PubMed ID: 21501559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of cAMP/EPAC/Akt signaling in the antiproteolytic effects of pentoxifylline on skeletal muscles of diabetic rats.
    Arcaro CA; Assis RP; Zanon NM; Paula-Gomes S; Navegantes LCC; Kettelhut IC; Brunetti IL; Baviera AM
    J Appl Physiol (1985); 2018 Mar; 124(3):704-716. PubMed ID: 29357512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effect of pentoxifylline on reproductive parameters in diabetic male mice.
    Feyli SA; Ghanbari A; Keshtmand Z
    Andrologia; 2017 Feb; 49(1):. PubMed ID: 27135184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat.
    Dávila-Esqueda ME; Martínez-Morales F
    Exp Diabesity Res; 2004; 5(4):245-51. PubMed ID: 15763938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects and clinical significance of pentoxifylline on the oxidative stress of rats with diabetic nephropathy.
    An ZM; Dong XG; Guo Y; Zhou JL; Qin T
    J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):356-361. PubMed ID: 26072073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.